Cystic Fibrosis Foundation expands partnership with Pfizer

11/20/2012 | Genetic Engineering & Biotechnology News

The Cystic Fibrosis Foundation committed up to $58 million over six years in a project with Pfizer to develop drugs targeting the Delta F508 genetic mutation associated with the disease. The CFF retains rights to any drug candidate Pfizer discovers but chooses not to develop.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI